Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)|
- Best over-all tumor response that occurs during 6 cycles of chemotherapy [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
- Survival [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
- Time to first response [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
- Time to progression [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
- Duration of response [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
- Completion of at least four cycles of chemotherapy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
- Toxicity profile [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 1998|
|Study Completion Date:||December 2002|
|Primary Completion Date:||September 2000 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the overall response rate to doxorubicin, docetaxel, and cyclophosphamide (ATC) in women with metastatic or locally advanced breast cancer. II. Determine survival, time to first response, time to progression, and duration of response in these patients. III. Evaluate the feasibility of administering ATC for at least 4 courses. IV. Evaluate the toxicity profile of ATC and its effect on cardiac function.
OUTLINE: Patients receive intravenous doxorubicin over 15 minutes on day 0, followed by intravenous cyclophosphamide over 30 minutes. An hour after the end of the doxorubicin infusion, intravenous docetaxel is administered over 1 hour. Patients receive courses every 21 days until disease progression or unacceptable toxic effects are observed. When the maximum dose of doxorubicin is reached, treatment continues with docetaxel and cyclophosphamide. Patients with locally advanced breast cancer receive chemotherapy for at least 2 courses after documented response. Patients are followed every 6 weeks.
PROJECTED ACCRUAL: Approximately 89 patients will be accrued to this study within 14 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003352
Show 166 Study Locations
|Principal Investigator:||Norman Wolmark, MD||NSABP Foundation, Inc.|